Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-06-12
2007-06-12
Fay, Zohreh A. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S912000
Reexamination Certificate
active
10436902
ABSTRACT:
Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.
REFERENCES:
patent: 4755388 (1988-07-01), Heath et al.
patent: 5424321 (1995-06-01), Hellberg et al.
patent: 5431907 (1995-07-01), Abelson et al.
patent: 5516522 (1996-05-01), Peyman et al.
patent: 5527810 (1996-06-01), Ornstein
patent: 5597809 (1997-01-01), Dreyer
patent: 5602156 (1997-02-01), Kohn
patent: 5623051 (1997-04-01), Caterall et al.
patent: 5710165 (1998-01-01), Kapin et al.
patent: 6509355 (2003-01-01), Collier, Jr.
patent: 6573280 (2003-06-01), Dreyer
patent: WO 90/06118 (1990-06-01), None
patent: WO 91/02497 (1991-03-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 95/22979 (1995-08-01), None
Machamer (1978) British J. Ophthal. 62:737.
Hilton et al (1983) Ophthalmology 90:121.
Constable I: “Biological and Therapeutic Aspects of Proliferative Vitreoretinopathy” Japanese Journal of Ophthalmology, vol. 31, No. 4, 1987, pp. 513-520, XP008054876.
Uchida N. et al: “Glutamate Stimulates Proliferation of Retinal Pigment Epithelium and Its BFGF Expression Through NMDA Receptor Activation”, vol. 71, No. Suppl. 1, Mar. 20, 1996, p. 274P, XP008040806.
Murphy T L et al: “Migration of retinal pigment epithelium cells in vitro is regulated by protein kinase C”, Experimental Eye Research, vol. 60, No. 6, Jun. 1995, pp. 683-695, XP-002102540.
Uchida N. et al: “Gltamate-Stimulated Proliferation of Rat Retinal Pigment Epithelium: Through NMDA Receptor Activation and BFGF Expression”, Investigative Ophthalmology & Visual Science, vol. 37, No. 3, Apr. 21, 1996, pp. S388, XP008040803.
Sakamoto T et al: “Vitamin E Succinate Inhibits Proliferation and Migration of Retinal Pigment Epithelial Cells in Vitro-Therapeutic Implication for Proliferative Vitreoretinopathy”, Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 234, No. 3, Mar. 1996, XP008040829.
Hackett S. et al: Cyclic 3′,5′-Adenosine Monophosphate Modulates Retinal Pigment Epithelial Cell Migration in Vitro, vol. 104, No. 11, Nov. 1986, pp. 1688-1692, XP008054877.
Hackett S. et al: “Implication of Protein Carboxymethylation in Retinal Pigment Epithelial Cell Chemotaxis”, Ophthalmic Research, vol. 20, No. 1, 1988, pp. 54-59.
Wagner M. et al: “Effects of Pharmacological Modulation of Intracellular Signalling Systems on Retinal Pigment Epithelial Cell Attachment to Extracellular Matrix Protein”, Current Eye Research, vol. 14, No. 5, May 1995, pp. 373-384.
Kalloniatis M.:“Amino Acids in Neurotransmission and Disease”, Journal of the American Optometric Assoc., vol. 66, No. 12, Dec. 1995, pp. 750-757, XP008053708.
Solberg Y et al: “Treatment of Laser-Induced Retinal Injuries by Neuroprotection”, SPIE, vol. 2974, 1997, pp. 158-165.
Ishikawa S. et al: “Alteration of Glutamine Concentration in the Vitreous Humor in Patients with Proliferative Vitreoretinopathy”, Current Eye Research, vol. 14, No. 3, Mar. 1995, pp. 191-197, XP008053697.
Haberecht M. et al: “N-Methyl-D-Aspartate-Mediated Glutamate Toxicity in the Developing Rabbit Retina” Journal of Neuroscience Research, vol. 47, No. 4, Feb. 15, 1997, pp. 416-426, XP008040828.
Uchida et al: “Glutamate-Stimulated Proliferation of Rat Retinal Pigment Epithelial Cells”, European Journal of Pharmacology, vol. 343, No. 2/3, Feb. 19, 1998, pp. 265-273, XP008040812.
Parsons, C.G., et al.,Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonistsin vitrowith anticonvulsive and motor impairment activityin vivo, Neuropharmacology, Oct. 1995; 34(10): 1239-58.
Zajaczkowski, W., et al.,Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists, Neurotox Res. Apr. 2000; 1(4):299-310.
Ehren, M., et al.,Inhibition of RPE proliferation, attachment and migration by carboxyamido-triazole(CAI),a drug which acts b modifying calcium mediated signal transduction, Investigative Ophthalmology and Visual Science, vol. 38, No. 4 part 1-2 May 1997, p. S754.
Hahn, J.M., et al.,Calcium channel blocker mediated inhibition of retinal pigment epithelial cell contraction of a collagen gels, Investigative Ophthalmology and Visual Science, vol. 37, No. 3, 1996, p. S393.
Hoffmann, S., et al.,Effect of the Calcium-antagonist verapamil on the serum induced proliferation of RPE cellsin vitro, Investigative Ophthalmology and Visual Science, vol. 37, No. 3, 1996, pp. S389.
Richter D., et al.Growth inhibition of intraocular proliferative explants underin vitroconditions by verapamil, Klinische Monatsblatter Fur Augenheilkunde, Sep. 1993, vol. 203, No. 3, pp. 206-211.
Allergan Inc.
Fay Zohreh A.
Johnson Brent A.
Voet Martin A.
LandOfFree
Calcium blockers to treat proliferative vitreoretinopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium blockers to treat proliferative vitreoretinopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium blockers to treat proliferative vitreoretinopathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816739